Bioidentical vs Body-Identical HRT
A Balanced View
If you’ve spent time researching menopause treatment online, you will have noticed how divided the conversation can be.
Some clinics dismiss compounded bioidentical hormones entirely. Others promote them as the only safe or “natural” option.
When opinions are that polarised, the truth usually sits somewhere in the middle.
Let’s clarify it properly.
What Do These Terms Actually Mean?
Both body-identical and bioidentical hormones are structurally identical to the hormones your body produces naturally.
The difference is not the molecule. It is the manufacturing and licensing pathway.
Licensed body-identical HRT refers to preparations such as transdermal oestradiol and micronised progesterone that are produced by pharmaceutical manufacturers and hold formal marketing authorisation.
Compounded bioidentical HRT refers to prescriptions prepared individually by specialist compounding pharmacies. These may allow flexibility in dose or combination when clinically required.
Both use pharmaceutical-grade hormones identical to endogenous hormones.
The distinction lies in authorisation and standardisation, not in whether one is “natural” and the other “synthetic.”
What Do Professional Guidelines Say
The British Menopause Society advises that compounded bioidentical HRT is not routinely recommended. Their position reflects:
- Greater published outcome data for licensed preparations
- The availability of regulated alternatives
- Limited evidence supporting routine saliva-based dose adjustment
These are reasonable population-level safety principles. However, guidelines are written for broad application. Clinical medicine is practised with individuals.
Are Compounded Hormones Unregulated?
You may have read that compounded hormones are “unregulated.” That is not accurate.
In the UK, specialist compounding pharmacies are registered with the General Pharmaceutical Council and operate within the Human Medicines Regulations framework. They are inspected and must comply with defined professional and manufacturing standards. The hormones used are pharmaceutical-grade and produced under Good Manufacturing Practice standards.
The key difference is this:
Licensed products undergo large commercial trial programmes tied to marketing authorisation.
Compounded prescriptions are prepared for individual patients and therefore do not follow that commercial licensing pathway.
That distinction matters in terms of evidence hierarchy. It does not mean absence of oversight.
What Does the Evidence Show?
Licensed body-identical oestradiol and micronised progesterone have reassuring safety data and are appropriate for many women.
For compounded formulations, large-scale outcome trials are more limited. That reflects differences in commercial licensing rather than differences in molecular structure.
The pharmacology of oestradiol, progesterone and testosterone is well established. What determines safety in practice is appropriate indication, careful dosing and ongoing review.
Medicine rarely operates in absolutes
When Might Compounding Be Considered?
For many women, licensed body-identical HRT works extremely well and should be first-line.
However, some women:
- Do not tolerate standard progesterone regimens
- Require dose adjustments outside available strengths
- Have persistent symptoms despite optimisation
- Need combinations not commercially available
In such cases, carefully supervised compounded therapy may be considered.
The key word is supervised.
Compounding should be clinically justified, not trend-driven.
What About Hormone Testing?
A single blood test taken in isolation, such as FSH, taken in isolation, is not a reliable way to decide on hormone replacement requirements
However, broader hormone assessment, when integrated with full clinical evaluation, may offer additional insight in complex cases.
Testing should inform judgement, not replace it.
My Position
I practise within established menopause guidance, including that of the British Menopause Society.
Licensed body-identical preparations are often entirely appropriate and effective.
Where individual circumstances require flexibility, intolerance management or bespoke dosing, compounded bioidentical therapy may be considered within a structured medical framework.
This is not about rejecting pharmaceutical medicine. Nor is it about embracing hype. It is about applying evidence thoughtfully to the individual woman in front of you. Menopause care should be balanced, proportionate and personalised.
If you would like to discuss which approach may be appropriate for you, consultations are available in clinic and remotely across the UK.
